Sulthiame, an oral carbonic anhydrase inhibitor, cut apnea events in the FLOW Phase 2 trial by roughly 16–35% depending on dose, suggesting a drug option for patients with moderate to severe obstructive sleep apnea (OSA) who cannot tolerate CPAP. The result is promising but not a universal replacement for device therapy: the trial ran 15 weeks, side effects rose with dose, and larger Phase 3 studies are still needed to confirm long-term safety and cardiovascular effects.
FLOW Phase 2 findings: the numbers that matter
The FLOW trial enrolled 298 adults with untreated moderate to severe OSA and randomized them to sulthiame 100 mg, 200 mg, or 300 mg once daily or placebo for 15 weeks, with results published in The Lancet. Compared with placebo, average reductions in the apnea‑hypopnea index (AHI) were approximately 16% at 100 mg, ~30% at 200 mg, and ~35% at 300 mg, and those gains were accompanied by measurable improvements in overnight oxygen saturation and daytime sleepiness.
There were no serious adverse events reported in the 15‑week study, but tolerability was dose‑dependent: higher doses produced more side effects and some participant withdrawals. These trial specifics — enrollment size, dosing arms, duration, and primary outcomes — are the strongest signal we currently have about sulthiame’s clinical effect size and trade‑offs.
How sulthiame works versus mechanical therapies
Sulthiame targets neuromuscular control of breathing rather than physically propping the airway open. Pharmacologically, it stabilizes respiratory drive and increases upper‑airway muscle tone so the airway is less likely to collapse during sleep; CPAP, by contrast, prevents collapse with positive pressure. That mechanistic distinction matters because it explains why sulthiame could help patients who struggle with CPAP adherence but whose OSA has a substantial neuromuscular component.
The drug is being developed for OSA by Apnimed in partnership with Shionogi, building on sulthiame’s clinical history outside the U.S. (including use in childhood epilepsy). Developers have emphasized the need for multiple therapeutic approaches to a heterogeneous condition like OSA, which helps explain why a neuromuscular‑targeted drug is entering trials alongside device‑based strategies.
Side effects, thresholds, and clear stop signals
The most common adverse event was intermittent paresthesia (tingling), which rose with dose and reached as high as 57% at the 300 mg dose; headaches and mild respiratory symptoms were also reported. Although no serious adverse events occurred in FLOW, some participants discontinued at higher doses because of tolerability. Clinicians should treat persistent or severe paresthesia, new or worsening respiratory symptoms, or a lack of oxygenation improvement as signals to pause and reassess therapy.
| Dose | Approx. AHI reduction vs placebo | Tolerability notes / stop checkpoints |
|---|---|---|
| 100 mg once daily | ~16% | Lower side‑effect burden; consider as starting dose to judge benefit/tolerance. |
| 200 mg once daily | ~30% | Greater efficacy but more paresthesia/headache; monitor symptoms and oxygenation. |
| 300 mg once daily | ~35% | Highest efficacy in FLOW but paresthesia occurred in up to 57%; some withdrawals noted. |
Practical use: who, how to start, and what to measure
Sulthiame is most relevant for adults with objectively confirmed moderate to severe OSA who cannot tolerate CPAP or other mechanical treatments. A realistic clinical approach from the FLOW data is to start at a lower dose (100 mg nightly), reassess symptoms and objective measures after several weeks, and only uptitrate if benefit outweighs side effects. Because FLOW ran 15 weeks, clinicians should be cautious about long‑term use until Phase 3 results evaluate sustained efficacy and cardiovascular/metabolic outcomes.
Monitoring should include repeat sleep testing (AHI and oxygen saturation) and symptom scales for daytime sleepiness; stop or reduce dose if AHI and oxygenation do not improve, if paresthesia is persistent or troublesome, or if new cardiorespiratory concerns appear. Watch for upcoming Phase 3 readouts — those trials will be the next checkpoint for expanding use beyond CPAP‑intolerant patients.
Short Q&A
Is sulthiame a replacement for CPAP? No — FLOW shows meaningful AHI reductions but not elimination of OSA, and CPAP remains first‑line for many. Sulthiame is best viewed as an alternative for patients who cannot use CPAP.
How quickly do benefits appear? FLOW measured outcomes over 15 weeks; improvements in AHI, oxygenation, and sleepiness were detected within that timeframe, so reassessment after several weeks to months is reasonable.
What are clear reasons to stop treatment? Severe or intolerable paresthesia (noted up to 57% at 300 mg), worsening oxygenation, or no objective AHI improvement on follow‑up sleep testing are practical stop signals.